ProLung Selected to Participate at Upcoming Cavendish Global Health Impact Forum
May 04, 2017
Salt Lake City, UT, May 4, 2017 — ProLung, Inc., a leader in innovative predictive analytics technology and non-invasive biomarkers for the risk stratification of lung cancer, announced today it has been selected to present at the upcoming Cavendish Global Health Impact Forum taking place May 7-9, 2017 in Washington, DC, co-hosted with the Virginia Biotechnology Association (VirginiaBio).
As part of ProLung’s awareness campaign to further increase corporate visibility among the scientific, financial, and philanthropic communities, ProLung recently became a member of Cavendish Global. ProLung will utilize the Cavendish Global platform to educate and further broaden awareness for ProLung’s mission to help save the lives of historically underserved lung cancer patients. The Company is fulfilling its mission through its non-invasive predictive analytics platform, the ProLung Test which aids in the risk stratification of indeterminate pulmonary nodules.
“We are honored to be selected to present at Cavendish’s unique event, and it is further recognition of our innovative approach to addressing the need for early detection of lung cancer with our breakthrough predictive analytics’ device. Given that lung cancer is the leading cause of cancer deaths worldwide, killing more individuals than colorectal, breast, pancreatic, and prostate cancers combined, the need for early detection has significant impact,” stated Steven Eror, President and CEO of ProLung. “ProLung recently became a member of Cavendish Global and is looking forward to its participation in the organization. Its members include many of the world’s most accomplished scientists, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people globally.”
Michael Moffat, Cavendish co-founder and Chairman explains, “With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies to identify organizations that meet the required standard of excellence. The quality and originality of ProLung’s research and scientific insights into early detection of lung cancer positions them to make a major contribution in addressing the unmet need to reduce the time required to detect and diagnose lung cancer.”
About ProLung, Inc.
ProLung’s mission is to make a difference in time for lung cancer patients. ProLung is a leader in innovative predictive analytics technology and non-invasive biomarkers for the risk stratification of lung cancer. The Company develops, tests, and commercializes solutions which may shorten the time to diagnosis and expand the therapeutic window for lung cancer patients. ProLung’s predictive analytics platform for lung cancer risk stratification is approved for sale in the European Economic Area and for investigational use only in the US.
For further information, contact:
Director of Marketing and Business Development
Investor relations information, contact:
Jennifer K. Zimmons, Ph.D.
Zimmons International Communications, Inc.
757 E. South Temple Suite 150
Salt Lake City, Utah 84102
About Cavendish Global
Cavendish Global is a peer-to-peer community of paradigm-changing innovators in health and the life sciences; over 200 leading family offices, philanthropists, foundations and impact investors; key opinion leaders and renown institutional partners that share a passion for well-conceived impact investing, sustainable philanthropy and delivering transformative impact. Cavendish provides the resources for innovators to advance their impactful work from mind to marketplace — through connectivity, advisory services, access to key opinion leaders and capital opportunities. Together, the Cavendish community bridges the gaps and accelerates innovation. Cavendish will host Forums in 2017 in Washington, DC, Chicago and Boston.
For more information: www.cavendishglobal.com
For further information, contact:
Director, Corporate Communications